摘要
目的:观察痰热清注射液联合布地奈德治疗肺炎支原体肺炎(MPP)患儿的效果。方法:回顾性分析2023年1月至2024年1月该院收治的100例MPP患儿的临床资料,根据治疗方式不同将其分为对照组与观察组各50例。对照组采用布地奈德治疗,观察组在对照组基础上联合痰热清注射液治疗。比较两组临床疗效,治疗前后炎性因子[白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、γ干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)]水平,以及不良反应发生率、复发率。结果:观察组治疗总有效率为98.00%(49/50),高于对照组的84.00%(42/50),差异有统计学意义(P<0.05);治疗后,两组IL-2水平均高于治疗前,且观察组高于对照组,两组IL-4、IFN-γ、TNF-α水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组复发率为4.00%(2/50),低于对照组的18.00%(9/50),差异有统计学意义(P<0.05)。结论:痰热清注射液联合布地奈德治疗MPP患儿可提高治疗总有效率,改善炎性因子水平,以及降低复发率,效果优于单纯布地奈德治疗。
Objective:To observe effects of Tanreqing injection combined with Budesonide in treatment of children with mycoplasma pneumonia(MPP).Methods:A retrospective analysis was conducted on the clinical data of 100 children with MPP admitted to this hospital from January 2023 to January 2024.They were divided into control group and observation group based on different treatment methods,50 cases in each group.The control group was treated with Budesonide,while the observation group received Tanreqing injection treatment on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[interleukin-2(IL-2),interleukin-4(IL-4),interferon-γ(IFN-γ),and tumor necrosis factor-α(TNF-α)]before and after the treatment,the incidence of adverse reactions,and the recurrence rate were compared between the two groups.Results:The total effective rate in the observation group was 98.00%(49/50),which was higher than 84.00%(42/50)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of IL-2 in the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of IL-4,IFN-γ,and TNF-αin the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The recurrence rate in the observation group was 4.00%(2/50),which was lower than 18.00%(9/50)in the control group,and the difference was statistically significant(P<0.05).Conclusions:The combination of Tanreqing injection and Budesonide in the treatment of the children with MPP can improve the overall treatment effects,reduce the inflammatory factor levels,and decrease the recurrence rate.Moreover,it is superior to simple Budesonide treatment.
作者
轩欢欢
崔文娟
李培培
XUAN Huanhuan;CUI Wenjuan;LI Peipei(Pediatrics Department of Zhengzhou Second Hospital,Zhengzhou 450000 Henan,China)
出处
《中国民康医学》
2026年第1期123-125,共3页
Medical Journal of Chinese People’s Health
关键词
儿童
支原体肺炎
痰热清注射液
布地奈德
炎性因子
复发率
不良反应
Children
Mycoplasma pneumonia
Tanreqing injection
Budesonide
Inflammatory factor
Recurrence rate
Adverse reaction
